In our previous study, we used a Bifidobacterium breve as a delivery vector of IL-24 gene therapy (B. breve-IL24) for head and neck squamous cell carcinoma in vivo and discovered that B. breve-IL24 offers a novel, safe, and clinically acceptable therapeutic approach for tumor therapy (18). Here, IL24 is linked to head and neck squamous cell carcinoma.